<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377819</url>
  </required_header>
  <id_info>
    <org_study_id>20050234</org_study_id>
    <nct_id>NCT00377819</nct_id>
  </id_info>
  <brief_title>Study of Transitioning From Alendronate to Denosumab</brief_title>
  <official_title>A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of transitioning postmenopausal women on
      current alendronate therapy to denosumab. Endpoints studied will include bone mineral
      density, bone turnover markers and bone histology in a subset of subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Total Hip Bone Mineral Density</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using [(3 month value - baseline value) / baseline value]*100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">504</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate</intervention_name>
    <description>70 mg oral QW</description>
    <arm_group_label>alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab (AMG 162)</intervention_name>
    <description>60 mg SC q 6 mos</description>
    <arm_group_label>denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal females 55 yrs or older

          -  Received alendronate therapy for osteoporosis for at least 6 months prior to entry
             into study

          -  Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and
             ≥ -4

        Exclusion Criteria:

          -  Vitamin D deficiency

          -  Administration of intravenous bisphosphonate, or

          -  fluoride (except for dental treatment) or

          -  strontium ranelate

          -  Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives
             (eg; teriparatide) within the last year

          -  Administration of any bisphosphonate other than alendronate (ALN) within 1 year of
             screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.</citation>
    <PMID>19594293</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <results_first_submitted>July 1, 2010</results_first_submitted>
  <results_first_submitted_qc>July 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2010</results_first_posted>
  <disposition_first_submitted>November 19, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2009</disposition_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>RANKL</keyword>
  <keyword>RANK</keyword>
  <keyword>denosumab</keyword>
  <keyword>AMG 162</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>bone turnover</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>clinical trial</keyword>
  <keyword>postmenopausal osteoporosis</keyword>
  <keyword>alendronate</keyword>
  <keyword>total hip bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 02-Oct-2006 Last Subject Enrolled: 07-Mar-2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alendronate 70 mg QW</title>
          <description>70 mg alendronate once weekly (QW) orally plus placebo for denosumab subcutaneously once every 6 months (Q6M)</description>
        </group>
        <group group_id="P2">
          <title>Denosumab 60 mg Q6M</title>
          <description>60 mg denosumab administered subcutaneously once every 6 months (Q6M) plus placebo for alendronate once weekly (QW) orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alendronate 70 mg QW</title>
          <description>70 mg alendronate once weekly (QW) orally plus placebo for denosumab subcutaneously once every 6 months (Q6M)</description>
        </group>
        <group group_id="B2">
          <title>Denosumab 60 mg Q6M</title>
          <description>60 mg denosumab administered subcutaneously once every 6 months (Q6M) plus placebo for alendronate once weekly (QW) orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="251"/>
            <count group_id="B2" value="253"/>
            <count group_id="B3" value="504"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.2" spread="7.7"/>
                    <measurement group_id="B2" value="66.9" spread="7.8"/>
                    <measurement group_id="B3" value="67.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Total Hip Bone Mineral Density</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Participants with non-missing baseline evaluation and at least 1 non-missing post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
            <description>70 mg alendronate once weekly (QW) orally plus placebo for denosumab subcutaneously once every 6 months (Q6M)</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>60 mg denosumab administered subcutaneously once every 6 months (Q6M) plus placebo for alendronate once weekly (QW) orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip Bone Mineral Density</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
          <population>Participants with non-missing baseline evaluation and at least 1 non-missing post-baseline evaluation.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.76" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.61" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -0.35%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Based on repeated measures model adjusting for treatment, length of prior alendronate stratification variable, visit, baseline value, machine type, treatment by visit interaction, and baseline value by machine type interaction</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Participants with non-missing baseline evaluation and at least 1 non-missing post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
            <description>70 mg alendronate once weekly (QW) orally plus placebo for denosumab subcutaneously once every 6 months (Q6M)</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>60 mg denosumab administered subcutaneously once every 6 months (Q6M) plus placebo for alendronate once weekly (QW) orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using [(12 month value - baseline value) / baseline value]*100.</description>
          <population>Participants with non-missing baseline evaluation and at least 1 non-missing post-baseline evaluation.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="1.44" upper_limit="2.26"/>
                    <measurement group_id="O2" value="3.03" lower_limit="2.63" upper_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -0.22%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated Measures Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Based on repeated measures model adjusting for treatment, length of prior alendronate stratification variable, visit, baseline value, machine type, treatment by visit interaction, and baseline value by machine type interaction</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)</title>
        <description>Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using [(3 month value - baseline value) / baseline value]*100.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>Participants with non-missing baseline evaluation and non-missing post-baseline evaluation at month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
            <description>70 mg alendronate once weekly (QW) orally plus placebo for denosumab subcutaneously once every 6 months (Q6M)</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
            <description>60 mg denosumab administered subcutaneously once every 6 months (Q6M) plus placebo for alendronate once weekly (QW) orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)</title>
          <description>Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using [(3 month value - baseline value) / baseline value]*100.</description>
          <population>Participants with non-missing baseline evaluation and non-missing post-baseline evaluation at month 3.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" lower_limit="-29.4" upper_limit="25.1"/>
                    <measurement group_id="O2" value="-63.3" lower_limit="-78.5" upper_limit="-38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Van Elteren Stratified Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alendronate 70 mg QW</title>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Periodontal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ameloblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nodular fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

